Skip to main content
. 2017 Jun 28;8(43):74170–74177. doi: 10.18632/oncotarget.18819

Figure 2.

Figure 2

(A) Analysis of PD-L1 mRNA expression in de-novo GBM and different recurrence stages. (B) Immunohistochemistry (IHC) of PD-L1 in paired de-novo/1st recurrent GBM. (C) PD-L1 expression values of 874 patients from public available databases in de-novo and recurrent GBM.